Oslo, Norway, 5 February 2026 – AdjuTec Pharma AS, a privately held company developing antibiotic resistance breakers, today announces that Venus Remedies Ltd. (India) has successfully completed an in vitro susceptibility study using AdjuTec Pharma’s lead product APC301 in a collection of Indian multidrug-resistant pathogens.
AdjuTec Pharma and Venus Remedies share a joint mission to address the global health threat against Antimicrobial Resistant (AMR). AMR directly causes ∼1.3 million global deaths annually and is projected to cause ∼39 million accumulated global deaths by 2050. If left unchecked, AMR is poised to surpass the number of cancer deaths, posing a substantial threat to global health. In India, meropenem - a last resort antibiotic, reached a record low susceptibility of only 35% in Klebsiella pneumonia in 2024 (ICMR 2025). Unless immediate and more decisive actions are taken to address AMR, the global economy may suffer annual losses of $1.7 trillion by 2050 (World bank).
AdjuTec Pharma has developed a novel technology that selectively inactivates a critical bacterial resistance mechanism, thereby restoring the efficacy of commercially available antibiotics. Recognizing India as a critical testing ground, AdjuTec Pharma has partnered with the Indian research-based pharmaceutical company Venus Remedies. As a part of this collaboration, Venus Medicine Research Centre (VMRC – An R&D division of Venus Remedies) tested AdjuTec Pharma’s lead product APC301 in an Indian collection of 303 multidrug-resistant E.coli and Klebsiella pneumonia, so called Enterobacterales. The study was recently completed and showed that >95% of these bacteria were highly susceptible to APC301. Enterobacterales are very important pathogens causing complicated urinary tract, lung and blood stream infections.
Venus Remedies is an innovator and leading manufacturer of antimicrobial therapeutics. Our combined technologies and competencies hold promise for tackling India’s growing endemic AMR crisis through this collaboration.
AdjuTec Pharma AS, CEO, Jethro Holter said:
AdjuTec Pharma and Venus Remedies share a joint mission to address the global health threat against Antimicrobial Resistant (AMR). AMR directly causes ∼1.3 million global deaths annually and is projected to cause ∼39 million accumulated global deaths by 2050. If left unchecked, AMR is poised to surpass the number of cancer deaths, posing a substantial threat to global health. In India, meropenem - a last resort antibiotic, reached a record low susceptibility of only 35% in Klebsiella pneumonia in 2024 (ICMR 2025). Unless immediate and more decisive actions are taken to address AMR, the global economy may suffer annual losses of $1.7 trillion by 2050 (World bank).
AdjuTec Pharma has developed a novel technology that selectively inactivates a critical bacterial resistance mechanism, thereby restoring the efficacy of commercially available antibiotics. Recognizing India as a critical testing ground, AdjuTec Pharma has partnered with the Indian research-based pharmaceutical company Venus Remedies. As a part of this collaboration, Venus Medicine Research Centre (VMRC – An R&D division of Venus Remedies) tested AdjuTec Pharma’s lead product APC301 in an Indian collection of 303 multidrug-resistant E.coli and Klebsiella pneumonia, so called Enterobacterales. The study was recently completed and showed that >95% of these bacteria were highly susceptible to APC301. Enterobacterales are very important pathogens causing complicated urinary tract, lung and blood stream infections.
Venus Remedies is an innovator and leading manufacturer of antimicrobial therapeutics. Our combined technologies and competencies hold promise for tackling India’s growing endemic AMR crisis through this collaboration.
AdjuTec Pharma AS, CEO, Jethro Holter said:
“We are delighted to collaborate with Venus Remedies, a renowned Indian company, with a shared purpose and commitment to develop more effective antibiotics to combat the escalating global AMR crisis. India has among the highest levels of multidrug resistance in the world. By using AdjuTec Pharma’s technology we have shown that we can restore the efficacy of meropenem in the vast majority of meropenem-resistant Enterobacterales in this Indian collection. AdjuTec Pharma is thrilled to continue its preclinical collaboration with Venus Remedies. This aligns perfectly with our strategy of partnering with leading and international pharmaceutical companies to bring our technologies to market.”
Venus Remedies Limited, CEO - VMRC, Saransh Chaudhary said:
“We are committed to addressing AMR by building strong international partnerships that accelerate anti-infectives innovation and strengthen the global response to multidrug-resistant infections. We are pleased to partner with AdjuTec Pharma, and APC-301 appears promising against MBL-producing Enterobacterales. We believe partnerships like these are critical to translating high-quality science into meaningful clinical impact, and we remain open to supporting the development of promising candidates that can improve treatment options in areas of high unmet medical need.”
About antimicrobial resistance (AMR)
https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
About AdjuTec Pharma AS
AdjuTec Pharma is a company that is dedicated to developing and providing novel antibiotic resistance breakers to the global market. The company´s technology offers a unique mechanism of action that inactivates bacterial defence enzymes and restores bacterial sensitivity to antibiotics. The company’s lead product is APC148, a selective zinc chelator targeting bacterial metallo-ß-lactamase (MBL) enzymes. The technology was invented by Professor Pål Rongved and his group at the Department of Pharmacy, University of Oslo. The company is located at ShareLab(Oslo Science Park), Gaustadalléen 21 - downtown Oslo.
For more information, please visit www.adjutecpharma.com or contact us at info@adjutecpharma.com
About Venus Remedies Limited
Venus Remedies Limited (NSE: VENUSREM, BSE: 526953) is a research-driven Indian pharmaceutical company with a strong global presence, focused on critical care and anti-infectives. The company is widely recognized for its leadership in AMR, supported by sustained investments in advanced R&D, patented therapies, and translational science. Venus is also a leading injectable manufacturers in the world, having presence in 100+ countries with a portfolio of many products spread over Europe, Australia, Africa, Asia-Pacific, Commonwealth States, Middle East, Latin America and Caribbean region. The company has nine globally benchmarked facilities in India and Germany, and 11 overseas marketing offices. Venus has a renowned state-of-the-art research and development facility - Venus Medicine Research Centre (VMRC), duly approved by the Department of Scientific & Industrial Research (DSIR), Government of India. Venus Remedies has a strong anti-infectives pipeline, and more than 150 patents, 70 trademarks and 12 copyrights for its innovative research products worldwide.
For more information, please visit www.venusremedies.com or contact us at anmolaggarwal@venusremedies.com